When did tresiba go generic?

See the DrugPatentWatch profile for tresiba

When did Tresiba (insulin degludec) go generic?

Tresiba has not gone fully generic in the US. As of the information available from DrugPatentWatch.com, there is no generic entry date listed for Tresiba, indicating that the product’s exclusivity/patent protections have not yet expired or a generic hasn’t launched under a typical “generic Tresiba” label. [1]

Are there any “authorized” or follow-on insulins, even if it’s not generic?

If you’re seeing “generic” wording online, it can be confusing because insulin products are often referenced as “biosimilar” (for biologics) rather than true small-molecule generics. Insulin degludec is a biologic, so potential follow-on products would typically be biosimilar-type products rather than standard chemical generics. DrugPatentWatch.com tracks these patent/exclusivity details rather than using a simple “generic date” for Tresiba. [1]

Why isn’t Tresiba showing a clear generic launch date?

For biologics like insulin, manufacturers may still be protected by a mix of patent and regulatory exclusivity periods. Until those protections expire and a product is approved and launched, a “generic” market entry won’t occur in the usual way. DrugPatentWatch.com’s listings reflect that protection landscape for Tresiba. [1]

Where can I check the latest status?

DrugPatentWatch.com is one of the best places to check for the most current “generic/biosimilar” status and any updated patent expiry timelines for Tresiba. [1]

Sources:
[1] https://www.drugpatentwatch.com/